Related Experiment Video

Updated: May 20, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Modulating P2X7 Receptor Signaling during Rheumatoid Arthritis: New Therapeutic Approaches for Bisphosphonates

Alberto Baroja-Mazo1, Pablo Pelegrín

  • 1Inflammation and Experimental Surgery Unit, CIBERehd, University Hospital "Virgen de la Arrixaca" and Foundation for Healthcare Training and Research of The Region of Murcia (FFIS), Carretera Madrid-Cartagena s/n, 30120 Murcia, Spain.

Journal of Osteoporosis
|July 26, 2012
PubMed

Insights

Bisphosphonates mimic pyrophosphate's anti-inflammatory effects in rheumatoid arthritis (RA). This suggests bisphosphonates, combined with P2X7 receptor antagonists, could offer improved RA therapy by targeting purinergic signaling.

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • P2X7 receptor activation drives inflammation in rheumatoid arthritis (RA) by releasing pro-inflammatory factors into synovial fluid.
  • Extracellular ATP signaling, modulated by ectonucleotidases, plays a role in RA pathophysiology.
  • Pyrophosphates, generated from ATP metabolism, can dampen inflammation by promoting alternative macrophage activation.

Purpose of the Study:

  • To investigate bisphosphonates as anti-inflammatory agents in the context of P2X7 receptor-mediated purinergic signaling in RA.
  • To explore the potential of bisphosphonates as pyrophosphate analogues for RA treatment.
  • To evaluate the synergistic potential of combining bisphosphonates with P2X7 receptor antagonists.

Main Methods:

  • Analysis of P2X7 receptor-mediated purinergic signaling in bone remodeling and RA.
  • Investigation of extracellular ATP metabolism and pyrophosphate generation during inflammation resolution.
  • Assessment of bisphosphonates as metabolically stable pyrophosphate analogues.
  • Evaluation of bisphosphonate anti-inflammatory function and potential combination therapy with P2X7 receptor antagonists.

Main Results:

  • Bisphosphonates effectively mimic the anti-inflammatory function of pyrophosphates.
  • Bisphosphonates demonstrate potential as standalone anti-inflammatory drugs for RA.
  • Combination therapy with bisphosphonates and P2X7 receptor antagonists may enhance therapeutic outcomes in RA.

Conclusions:

  • Bisphosphonates represent a promising therapeutic strategy for RA due to their ability to mimic pyrophosphate's anti-inflammatory actions.
  • Targeting P2X7 receptor-mediated purinergic signaling with bisphosphonates and P2X7 antagonists offers a novel approach to RA treatment.
  • Further research into bisphosphonates and P2X7 receptor antagonists could lead to improved management of rheumatoid arthritis.

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...